The Healthcare AI Stock Investors Will Proudly Brag About in 2035

When a mid-cap healthcare company delivers 51% revenue growth in a single year, it attracts attention. Hinge Health, which debuted on the public markets in May 2025, has done exactly that—posting revenues of $587.9 million for the year, a figure that outpaces growth rates from established tech giants like Nvidia and CrowdStrike. For investors hunting for the next decade’s success stories, this performance warrants closer examination. The stock has gained just 7% since its IPO, suggesting early believers may be getting in at a reasonable entry point before the broader market catches on.

The company’s long-term prospects are increasingly compelling. As employers face mounting healthcare expenses, they’re discovering that digitally-delivered physical therapy can dramatically reduce costs while improving employee outcomes. Hinge Health is capitalizing on this shift, establishing itself as the leader in what’s becoming a critical healthcare niche.

Addressing a $50+ Billion Market Opportunity

Market research from Grand View Research valued the U.S. physical therapy services sector at $50.2 billion in 2024, with projections to reach $76.6 billion by 2033. That’s a compound annual growth rate of 4.9%—steady, predictable expansion in a massive industry. Hinge Health is riding this wave aggressively.

In the fourth quarter alone, the company expanded its corporate client base by 25% year-over-year, reaching 2,830 employers. More telling: the population eligible for its services grew to 25 million people, and active platform engagement surged 47% to nearly 783,000 users. These metrics reveal explosive adoption among employers and employees alike, signaling that the company has discovered a genuine market need.

AI Technology as the Core Competitive Advantage

What sets Hinge Health apart isn’t just scale—it’s the technology underpinning its platform. The company uses artificial intelligence to automate and optimize physical therapy delivery, allowing employers to cut orthopedic surgery rates, reduce employee downtime, and maintain predictable care costs. This isn’t theoretical efficiency; it’s a practical solution addressing the healthcare industry’s most pressing challenge: runaway expenses.

Recent product innovations highlight the sophistication of its approach. In November 2025, Hinge Health unveiled Robin, an AI care assistant that helps patients recognize pain flares and communicate symptoms to physical therapists. The same announcement included movement analysis, powered by TrueMotion computer vision technology, which measures joint angles, symmetry, and endurance to create personalized health scores. Additionally, the company markets Enso, a wearable device that delivers targeted electrical pulses to reduce chronic pain and accelerate therapy timelines. These aren’t minor feature updates—they represent meaningful advancements in digital musculoskeletal health.

Financial Strength Approaching Profitability

Here’s where the investment case strengthens. Despite posting a net loss of $523.8 million in 2025 (largely reflecting acquisition and scaling costs), Hinge Health reported Q4 net income of $32 million, a 18.3% year-over-year improvement. The trajectory matters more than the current position.

Free cash flow growth of 65% to $61.5 million demonstrates that the business is generating real economic value. Trading at a price-to-FCF ratio below 19, the stock appears reasonably valued for a company in its growth phase. Management’s confidence showed in another way: the company approved a $250 million stock buyback program, signaling internal conviction about undervaluation.

The gross margin of 84% in Q4 reveals the inherent profitability of the business model. As the company scales and distributes its fixed costs across more customers, that margin advantage should compound.

The Path Forward

CEO Daniel Perez has indicated that Hinge Health views its current position in physical therapy as the foundation for broader healthcare automation. The company is eyeing expansion into other medical domains where AI-driven solutions could replicate its success. For a stock that has underperformed its revenue growth, this expansion optionality represents significant upside potential.

For 2026, management is guiding toward revenues of $732 million to $742 million, representing 25% growth at the midpoint. If the company continues executing and reaches profitability while maintaining double-digit growth, this is precisely the type of stock investors will be proud to have backed a decade from now.